

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BARABE TIMOTHY C</u> (Last) (First) (Middle) <u>C/O CARTESIAN THERAPEUTICS, INC.</u> <u>65 GROVE STREET</u> (Street) <u>WATERTOWN MA 02472</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Cartesian Therapeutics, Inc. [RNAC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/13/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$11	11/13/2023		D			10,328	(1)	07/28/2026	Common Stock	10,328	(1)	0	D	
Stock Option (Right to Buy)	\$17.47	11/13/2023		D			6,410	(2)	06/15/2027	Common Stock	6,410	(2)	0	D	
Stock Option (Right to Buy)	\$12.75	11/13/2023		D			10,000	(3)	06/14/2028	Common Stock	10,000	(3)	0	D	
Stock Option (Right to Buy)	\$3	11/13/2023		D			20,000	(4)	06/18/2030	Common Stock	20,000	(4)	0	D	
Stock Option (Right to Buy)	\$4.01	11/13/2023		D			40,000	(5)	03/29/2031	Common Stock	40,000	(5)	0	D	
Stock Option (Right to Buy)	\$3.31	11/13/2023		D			40,000	(6)	01/02/2032	Common Stock	40,000	(6)	0	D	
Stock Option (Right to Buy)	\$1.13	11/13/2023		D			87,500	(7)	01/01/2033	Common Stock	87,500	\$0.93	0	D	

Explanation of Responses:

- This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
- This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger.
- This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.
- This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
- This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
- This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
- This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of \$81,375, representing the difference between the exercise price of the option and \$2.06, the Cash-out Amount as applied in the Merger.

Remarks:

/s/ Matthew Bartholomae,
 Attorney-in-Fact for Timothy C. Barabe 11/15/2023
 C. Barabe

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.